Effective immediately, due to low test utilization and the high cost of maintaining proficiency, the Chromosome Analysis Breakage Study will no longer be offered by the Spectrum Health Cytogenetics Department.
If need arises for this test, please place an order for a Reference Miscellaneous (EPIC# LAB848) and enter “Test 140 DEB Breakage Study to Integrated Genetics” in the comments. The testing will be sent out through Spectrum Health Referrals Department to Integrated Genetics.
In December, serum and urine protein electrophoresis testing will be simplified and standardized. The only testing available will be:
In addition, on December 5, 2019, a new panel will be added which reflects expert recommendations for first line testing for monoclonal gammopathy, including plasma cell myeloma and most cases of amyloidosis, called “Monoclonal Gammopathy Screen”
To better align with our Allergy Specialists and reduce confusion and costs to patients, we have simplified and standardized our Allergy Panel offerings. These new panels will be available to order beginning Thursday, October 24, 2019. Also effective on this date, several of our old panels will be discontinued.
Effective September 1, 2019, the test Drug of Abuse Screen, Pain Clinic, Urine will be discontinued.
Earlier this year, Spectrum Health Regional Laboratory – Toxicology announced two new drug screen panels, Urine Drug Screen with Confirmation (23 Targets) and Urine Drug Screen with Confirmation (32 Targets) as replacement tests. For more information regarding these new tests please reference this post.
Effective January 1, 2019, Spectrum Health Regional Laboratory will no longer offer Magnesium, Red Blood Cell [LAB104] as an option for send out testing. This testing will no longer be available through Spectrum Health’s primary reference laboratory, Mayo Clinic Laboratories. This test will become obsolete on January 7, 2019, due to limited clinical utility.